ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-6235.7%−1735.2 pts over 5 years
Net margin
-3629.2%−228.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -71.6% | -36.0% | -19.1% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -6.5% | |
| Return on assets | – | – | -5.4% | |
| Current ratio | – | 9.99 | 18.37 | |
| Debt to equity | – | 0.09 | – | |
| Interest coverage | – | -381.2× | – | |
| Capex to revenue | – | 24.4% | 99.4% | |
| Diluted shares | – | 630M | 694M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Roivant Sciences generated $3.88B from operations and spent $1.34B on capital expenditure, dividends and share buybacks. 3% of that went back into the business.
Generated
$3.88B
Used
$1.34B
Capital expenditure$44.32M3%Dividends$00%Share buybacks$1.29B97%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3629.2%
×Asset turnover0.00×
×Equity multiplier1.21×
=Return on equity, FY2025-6.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3629.2% | 0.00× | 1.21× | -6.5% |
| FY2024 | -592.0% | 0.00× | 1.19× | -3.2% |
| FY2023 | 13294.2% | 0.01× | 1.35× | 122.1% |
| FY2022 | -3200.2% | 0.01× | 1.77× | -71.7% |
| FY2021 | -1528.9% | 0.02× | 1.50× | -48.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$299.77M
- Cash generatingOperating cash flow above zero-$750.35M
- Return on assets improvedROA up on the prior year-2.4% → -5.5%
- Earnings backed by cashOperating cash flow above net income-$750.35M vs -$299.77M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose33.47 → 18.37
- No dilutionShare count did not rise725M → 694M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00